Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

Published:2019-12 Issue:6 Volume:76 Page:782-789
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Niglio Scot A.,Jia Rachel,Ji Jiayi,Ruder Samuel,Patel Vaibhav G.,Martini Alberto,Sfakianos John P.,Marqueen Kathryn E.,Waingankar Nikhil,Mehrazin Reza,Wiklund Peter,Oh William K.,Mazumdar Madhu,Ferket Bart S.,Galsky Matthew D.

Publisher

Elsevier BV

Subject

Urology

Reference37 articles.

1. Cancer stat facts: bladder cancer;National Cancer Institute Surveillance Epidemiology and End Results Program,2018

2. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J Clin Oncol,2012

3. Molecular biology and targeted therapies for urothelial carcinoma;Seront;Cancer Treat Rev,2015

4. European Commission. Union Register of medicinal products for human use: pembrolizumab, KEYTRUDA. http://ec.europa.eu/health/documents/community-register/html/h1024.htm.

5. European Commission. Union Register of medicinal products for human use: Atezolizumab, Tecentriq. http://ec.europa.eu/health/documents/community-register/html/h1220.htm.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study;Advances in Therapy;2023-12-04

2. The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials;BJU International;2023-07-25

3. Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study;Frontiers in Oncology;2023-05-02

4. A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma;Value in Health;2023-04

5. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients;Future Oncology;2023-02